Mogamulizumab, an anti-CCR4 antibody, targets human T-lymphotropic virus type 1-infected CD8+ and CD4+ T cells to treat associated myelopathy

Journal of Infectious Diseases

Volumn 211, Issue 2, 2015, Pages 238-248

  Yamauchi, Junji ^a   Coler Reilly, Ariella ^a   Sato, Tomoo ^a   Araya, Natsumi ^a   Yagishita, Naoko ^a   Ando, Hitoshi ^a   Kunitomo, Yasuo ^a   Takahashi, Katsunori ^a   Tanaka, Yuetsu ^b   Shibagaki, Yugo ^a   Nishioka, Kusuki ^c   Nakajima, Toshihiro ^c   Hasegawa, Yasuhiro ^a   Utsunomiya, Atae ^d   Kimura, Kenjiro ^a   Yamano, Yoshihisa ^a  

^a ST MARIANNA UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^b UNIVERSITY OF THE RYUKYUS   (Japan)

^c TOKYO MEDICAL UNIVERSITY   (Japan)

^d IMAMURA BUN IN HOSPITAL   (Japan)

Author keywords

CCR4; CD8; HAM TSP; HTLV 1; mogamulizumab

Indexed keywords

CHEMOKINE RECEPTOR CCR4; GAMMA INTERFERON; INTERLEUKIN 10; INTERLEUKIN 2; INTERLEUKIN 4; INTERLEUKIN 6; KM 2760; MOGAMULIZUMAB; MONOCLONAL ANTIBODY; PREDNISOLONE; TAX PROTEIN; TUMOR NECROSIS FACTOR ALPHA; UNCLASSIFIED DRUG; CCR4 PROTEIN, HUMAN;

ADULT; AGED; ANTIVIRAL ACTIVITY; ARTICLE; CD4+ T LYMPHOCYTE; CD8+ T LYMPHOCYTE; CLINICAL ARTICLE; CONTROLLED STUDY; CYTOKINE PRODUCTION; CYTOTOXIC T LYMPHOCYTE; DRUG EFFICACY; DRUG TARGETING; FEMALE; FLOW CYTOMETRY; HUMAN; HUMAN CELL; HUMAN T CELL LEUKEMIA VIRUS 1; INFECTION CONTROL; MALE; NONHUMAN; PATHOGENESIS; PERIPHERAL BLOOD MONONUCLEAR CELL; PROTEIN EXPRESSION; PROTEIN SYNTHESIS INHIBITION; SPINAL CORD DISEASE; TROPICAL SPASTIC PARAPARESIS; VIRUS CELL INTERACTION; VIRUS LOAD; ANTAGONISTS AND INHIBITORS; DRUG EFFECTS; MIDDLE AGED; PARAPARESIS, TROPICAL SPASTIC; TREATMENT OUTCOME;

AGED; ANTIBODIES, MONOCLONAL, HUMANIZED; CD4-POSITIVE T-LYMPHOCYTES; CD8-POSITIVE T-LYMPHOCYTES; FEMALE; HUMANS; MALE; MIDDLE AGED; PARAPARESIS, TROPICAL SPASTIC; RECEPTORS, CCR4; TREATMENT OUTCOME;

EID: 84922505919     PISSN: 00221899     EISSN: 15376613     Source Type: Journal    
DOI: 10.1093/infdis/jiu438     Document Type: Article

References (46)

1. Gessain A, Barin F, Vernant JC. Antibodies to human T-lymphotropic virus type-I in patients with tropical spastic paraparesis. Lancet 1985; 2:407-10.
2. Osame M, Usuku K, Izumo S, et al. HTLV-I associated myelopathy, a new clinical entity. Lancet 1986; 1:1031-2.
3. Verdonck K, González E, Van Dooren S, Vandamme A, Vanham G, Gotuzzo E. Human T-lymphotropic virus 1: recent knowledge about an ancient infection. Lancet Infect Dis 2007; 7:266-81.
4. Ijichi S, Izumo S, Eiraku N, et al. An autoaggressive process against bystander tissues in HTLV-I-infected individuals: a possible pathomechanism of HAM/TSP. Med Hypotheses 1993; 41:542-7.
5. Nakagawa M, Nakahara K, Maruyama Y, et al. Therapeutic trials in 200 patients with HTLV-I-Associated myelopathy/tropical spastic paraparesis. J Neurovirol 1996; 2:345-55.
6. Izumo S, Goto I, Itoyama Y, et al. Interferon-Alpha is effective in HTLVI-Associated myelopathy: a multicenter, randomized, double-blind, controlled trial. Neurology 1996; 46:1016-21.
7. Olindo S, Lézin A, Cabre P, et al. HTLV-1 proviral load in peripheral blood mononuclear cells quantified in 100 HAM/TSP patients: a marker of disease progression. J Neurol Sci 2005; 237:53-9.
8. Taylor GP, Goon P, Furukawa Y, et al. Zidovudine plus lamivudine in human T-lymphotropic virus type-l-Associated myelopathy: A randomised trial. Retrovirology 2006; 3:63.
9. Macchi B, Balestrieri E, Ascolani A, et al. Susceptibility of primary HTLV-1 isolates from patients with HTLV-1-Associated myelopathy to reverse transcriptase inhibitors. Viruses 2011; 3:469-83.
10. De Clercq E. A cutting-edge view on the current state of antiviral drug development. Med Res Rev 2013; 33:1249-77.
11. Wattel E, Vartanian JP, Pannetier C, Wain-Hobson S. Clonal expansion of human T-cell leukemia virus type I-infected cells in asymptomatic and symptomatic carriers without malignancy. J Virol 1995; 69:2863-8.
12. Cavrois M, Leclercq I, Gout O, Gessain A, Wain-Hobson S, Wattel E. Persistent oligoclonal expansion of human T-cell leukemia virus type 1-infected circulating cells in patients with tropical spastic paraparesis/HTLV-1 associated myelopathy. Oncogene 1998; 17:77-82.
13. Ishida T, Joh T, Uike N, et al. Defucosylated anti-CCR4 monoclonal antibody (KW-0761) for relapsed adult T-cell leukemia-lymphoma: a multicenter phase II study. J Clin Oncol 2012; 30:837-42.
14. Ishida T, Utsunomiya A, Iida S, et al. Clinical significance of CCR4 expression in adult T-cell leukemia/lymphoma: its close association with skin involvement and unfavorable outcome. Clin Cancer Res 2003; 9:3625-34.
15. Niwa R, Shoji-Hosaka E, Sakurada M, et al. Defucosylated chimeric anti-CC chemokine receptor 4 IgG1 with enhanced antibodydependent cellular cytotoxicity shows potent therapeutic activity to T-cell leukemia and lymphoma. Cancer Res 2004; 64:2127-33.
16. Ishii T, Ishida T, Utsunomiya A, et al. Defucosylated humanized anti-CCR4 monoclonal antibody KW-0761 as a novel immunotherapeutic agent for adult T-cell leukemia/lymphoma. Clin Cancer Res 2010; 16:1520-31.
17. Yamano Y, Araya N, Sato T, et al. Abnormally high levels of virusinfected IFN-?+CCR4+CD4+CD25+ T cells in a retrovirus-Associated neuroinflammatory disorder. PLoS One 2009; 4:e6517.
18. Araya N, Sato T, Ando H, et al. HTLV-1 induces a Th1-like state in CD4+CCR4+ T cells. J Clin Invest 2014; 124:3431-42.
19. Nagai M, Brennan MB, Sakai JA, Mora CA, Jacobson S. CD8(+) T cells are an in vivo reservoir for human T-cell lymphotropic virus type I. Blood 2001; 98:1858-61.
20. Inaoki M, Sato S, Shirasaki F, Mukaida N, Takehara K. The frequency of type 2 CD8+ T cells is increased in peripheral blood from patients with psoriasis vulgaris. J Clin Immunol 2003; 23:269-78.
21. Cho BA, Sim JH, Park JA, et al. Characterization of effector memory CD8+ T cells in the synovial fluid of rheumatoid arthritis. J Clin Immunol 2012; 32:709-20.
22. Hieshima K, NagakuboD, Nakayama T, Shirakawa A, Jin Z, Yoshie O. Taxinducible production of CC chemokine ligand 22 by human T cell leukemia virus type 1 (HTLV-1)-infected T cells promotes preferential transmission of HTLV-1 to CCR4-expressing CD4+ T cells. J Immunol 2008; 180:931-9.
23. Osame M. Review of WHO Kagoshima meeting and diagnostic guidelines for HAM/TSP. In: Blattner WA, ed. Human retrovirology: HTLV. New York: Raven Press, 1990: 191-7.
24. Yamano Y, Nagai M, Brennan M, et al. Correlation of human T-cell lymphotropic virus type 1 (HTLV-1) mRNA with proviral DNA load, virus-specific CD8+ T cells, and disease severity in HTLV-1-Associated myelopathy (HAM/TSP). Blood 2002; 99:88-94.
25. Lee B, Tanaka Y, Tozawa H.Monoclonal antibody defining tax protein of human T-cell leukemia virus type-I. Tohoku J Exp Med 1989; 157:1-11.
26. Itoyama Y, Minato S, Kira J, et al. Spontaneous proliferation of peripheral blood lymphocytes increased in patients with HTLV-I-Associated myelopathy. Neurology 1988; 38:1302-7.
27. Tanner A, Bochner F, Caffin J, Halliday J, Powell L. Dose-dependent prednisolone kinetics. Clin Pharmacol Ther 1979; 25:571-8.
28. Toulza F, Heaps A, Tanaka Y, Taylor GP, Bangham CR. High frequency of CD4+FoxP3+ cells in HTLV-1 infection: inverse correlation with HTLV-1-specific CTL response. Blood 2008; 111:5047-53.
29. Shimizu Y, Takamori A, Utsunomiya A, et al. Impaired Tax-specific T-cell responses with insufficient control of HTLV-1 in a subgroup of individuals at asymptomatic and smoldering stages. Cancer Sci 2009; 100:481-9.
30. Ando H, Sato T, Tomaru U, et al. Positive feedback loop via astrocytes causes chronic inflammation in virus-Associated myelopathy. Brain 2013; 136:2876-87.
31. Machigashira K, Ijichi S, Nagai M, Yamano Y, Hall WW, Osame M. In vitro virus propagation and high cellular responsiveness to the infected cells in patients with HTLV-I-Associated myelopathy (HAM/TSP). J Neurol Sci 1997; 149:141-5.
32. Sakai JA, Nagai M, Brennan MB, Mora CA, Jacobson S. In vitro spontaneous lymphoproliferation in patients with human T-cell lymphotropic virus type I-Associated neurologic disease: predominant expansion of CD8+ T cells. Blood 2001; 98:1506-11.
33. Nagai M, Usuku K, Matsumoto W, et al. Analysis of HTLV-I proviral load in 202 HAM/TSP patients and 243 asymptomatic HTLV-I carriers: high proviral load strongly predisposes to HAM/TSP. J Neurovirol 1998; 4:586-93.
34. Iwanaga M, Watanabe T, Utsunomiya A, et al. Human T-cell leukemia virus type I (HTLV-1) proviral load and disease progression in asymptomatic HTLV-1 carriers: a nationwide prospective study in Japan. Blood 2010; 116:1211-9.
35. Geginat J, Lanzavecchia A, Sallusto F. Proliferation and differentiation potential of human CD8+ memory T-cell subsets in response to antigen or homeostatic cytokines. Blood 2003; 101:4260-6.
36. Kondo T, Takiguchi M. Human memory CCR4+CD8+ T cell subset has the ability to produce multiple cytokines. Int Immunol 2009; 21: 523-32.
37. Baek HJ, Zhang L, Jarvis LB, Gaston JS. Increased IL-4+ CD8+ T cells in peripheral blood and autoreactive CD8+ T cell lines of patients with inflammatory arthritis. Rheumatology (Oxford) 2008; 47:795-803.
38. Nagai M, Kubota R, Greten TF, Schneck JP, Leist TP, Jacobson S. Increased activated human T cell lymphotropic virus Type I (HTLVI) Tax11-19-specific memory and effector CD8+ cells in patients with HTLV-I-Associated myelopathy/tropical spastic paraparesis: correlation with HTLV-I provirus load. J Infect Dis 2001; 183:197-205.
39. Yasunaga J, Sakai T, Nosaka K, et al. Impaired production of naive T lymphocytes in human T-cell leukemia virus type I-infected individuals: its implications in the immunodeficient state. Blood 2001; 97:3177-83.
40. Joshi NS, Cui W, Chandele A, et al. Inflammation directs memory precursor and short-lived effector CD8+ T cell fates via the graded expression of T-bet transcription factor. Immunity 2007; 27:281-95.
41. Kannagi M, Hasegawa A, Kinpara S, Shimizu Y, Takamori A, Utsunomiya A. Double control systems for human T-cell leukemia virus type 1 by innate and acquired immunity. Cancer Sci 2011; 102:670-6.
42. Hanon E, Hall S, Taylor GP, et al. Abundant tax protein expression in CD4+ T cells infected with human T-cell lymphotropic virus type I (HTLV-I) is prevented by cytotoxic T lymphocytes. Blood 2000; 95: 1386-92.
43. Vine AM, Heaps AG, Kaftantzi L, et al. The role of CTLs in persistent viral infection: cytolytic gene expression in CD8+ lymphocytes distinguishes between individuals with a high or low proviral load of human T cell lymphotropic virus type 1. J Immunol 2004; 173:5121-9.
44. Hanon E, Stinchcombe JC, Saito M, et al. Fratricide among CD8+ T lymphocytes naturally infected with human T cell lymphotropic virus type I. Immunity 2000; 13:657-64.
45. Sugiyama D, Nishikawa H, Maeda Y, et al. Anti-CCR4 mAb selectively depletes effector-Type FoxP3+CD4+ regulatory T cells, evoking antitumor immune responses in humans. Proc Natl Acad Sci U S A 2013; 110:17945-50.
46. Ishida T, Ueda R. Immunopathogenesis of lymphoma: focus on CCR4. Cancer Sci 2011; 102:44-50.